SGMO Sangamo Therapeutics Inc

10,846

$0.4541

$0.0241

(5.61%)

Today

Watchers	10,846
52-Wk Low	$0.2911
52-Wk High	$3.76

Market Cap	$76.26M
Volume (M)	1.19M
52-Wk High	$3.76
52-Wk Low	$0.2911

Fundamentals

What To Know About RBC Capital's Downgrade of Sangamo TherapeuticsBenzinga • 29 days ago

Latest Ratings for SGMO DateFirmActionFromTo May 2021RBC CapitalInitiates Coverage OnOutperform Jan 2021StifelInitiates Coverage OnHold Dec 2020HC Wainwright & Co.AssumesBuy View More Analyst...

Share to Feed

Sangamo Therapeutics Inc (SGMO) Announces Q3 2023 Financial Results and Strategic UpdateGuruFocus • about 1 month ago

Company focuses on neurology-focused genomic medicine, announces restructuring and workforce reductionRelated Stocks: SGMO...

Sangamo Therapeutics Announces Strategic Update and Reports Third Quarter 2023 Financial ResultsBusiness Wire • about 1 month ago

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today announced recent business highlights, including progress on its strategic transformation and a corresponding...

Sangamo Therapeutics Announces Third Quarter 2023 Conference Call and WebcastBusiness Wire • about 1 month ago

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company has scheduled the release of its third quarter 2023 financial results after the market closes...

Sangamo Therapeutics to Present Pre-Clinical Data Showcasing Its Epigenetic Regulation for Neurology and CAR-Treg Research at the 30th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)Business Wire • about 1 month ago

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the European Society of Gene & Cell Therapy (ESGCT) has accepted six Sangamo abstracts for presentation at...

Sangamo Therapeutics to Present at the Jefferies Cell & Genetic Medicine SummitBusiness Wire • 2 months ago

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today announced that it will participate in the Jefferies Cell & Genetic Medicine Summit, to be held from September...

Analyst Ratings for Sangamo TherapeuticsBenzinga • 4 months ago

Latest Ratings for SGMO DateFirmActionFromTo May 2021RBC CapitalInitiates Coverage OnOutperform Jan 2021StifelInitiates Coverage OnHold Dec 2020HC Wainwright & Co.AssumesBuy View More Analyst Ratings for SGMO View the Latest Analyst Ratings read more...

Sangamo Therapeutics GAAP EPS of -$0.66 misses by $0.32, revenue of $6.84M misses by $8.49MSeekingAlpha.com: All News • 4 months ago

Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2023 Financial ResultsBusiness Wire • 4 months ago

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and second quarter 2023 financial results. I am extremely proud of our significant progress this quarter. We are pleased to have executed several business development deals...

Sangamo Therapeutics Q2 2023 Earnings PreviewSeeking Alpha - Healthcare • 4 months ago